Tick-borne viral encephalitis, unspecified
ICD-10 A84.9 is a billable code used to indicate a diagnosis of tick-borne viral encephalitis, unspecified.
Tick-borne viral encephalitis (TBE) is a viral infection that affects the central nervous system, primarily transmitted through the bite of infected ticks. The disease is endemic in certain regions, particularly in Europe and Asia, where the Ixodes ricinus and Ixodes persulcatus ticks are prevalent. The clinical presentation can range from mild flu-like symptoms to severe neurological complications, including encephalitis, meningitis, and myelitis. Patients may experience fever, headache, and fatigue, followed by neurological symptoms such as confusion, seizures, and motor deficits. The diagnosis is typically confirmed through serological testing for specific antibodies against the TBE virus. Vaccination is available and recommended for individuals at high risk, such as those living in endemic areas or engaging in outdoor activities in these regions. The unspecified designation in this code indicates that the specific type or severity of the encephalitis is not documented, which may complicate treatment and management decisions.
Detailed clinical history, laboratory results, and vaccination status.
Patients presenting with neurological symptoms after tick exposure.
Ensure serological tests are documented and specify the type of encephalitis when possible.
Neurological examination findings, imaging results, and treatment plans.
Patients with acute neurological deficits and a history of tick exposure.
Document all neurological assessments and any differential diagnoses considered.
Used to confirm diagnosis of TBE.
Document the reason for testing and results.
Infectious disease specialists should ensure comprehensive testing.
Symptoms can include fever, headache, fatigue, and neurological symptoms such as confusion, seizures, and motor deficits.
Diagnosis is typically made through clinical evaluation and confirmed with serological testing for TBE virus antibodies.
Yes, a vaccine is available and recommended for individuals at high risk, particularly in endemic areas.
